Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9846226 | 0.84 | PIK3CD (0.36) | ELANETP53ALDH1A1GLAL3MBTL1 | |
| SCHEMBL5573693 | 0.74 | MAPT (0.54) | MAPTLMNAGAATDP1ALOX15 | |
| SCHEMBL9265244 | 0.72 | APP (0.44) | MAPTRAB9ANPC1HDAC3HDAC4 | |
| SCHEMBL9432422 | 0.72 | ELANE (0.48) | MAPTLMNAGAATDP1RAB9A | |
| SCHEMBL2147325 | 0.72 | MAPT (0.48) | MAPTLMNAGAATDP1ALOX15 | |
| SCHEMBL9846349 | 0.71 | MAPT (0.50) | MAPTLMNAGAATDP1ALOX15 | |
| SCHEMBL9281450 | 0.71 | RAB9A (0.41) | MAPTLMNAGAATDP1ALOX15 | |
| SCHEMBL9431759 | 0.71 | RAB9A (0.41) | MAPTLMNAGAATDP1RAB9A | |
| SCHEMBL9268706 | 0.70 | RAB9A (0.48) | MAPTLMNARAB9AELANETP53 | |
| SCHEMBL9431768 | 0.67 | MAPT (0.54) | MAPTLMNARAB9AELANETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673830-B2 | COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | claimed |
| US-7211603-B1 | Enediyne compounds and methods related thereto | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2007-05-01 | — | — | US | disclosed |
| US-6987132-B1 | Enediyne compounds and methods related thereto | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2006-01-17 | — | — | US | disclosed |
| US-6828439-B1 | Compounds, composition, and methods for photodynamic therapy | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2004-12-07 | — | — | US | disclosed |
| US-6774141-B1 | INHIBIT REPLICATION OF RETROVIRUSES SUCH AS LYMPHADENOPATHY ASSOCIATED-, HUMAN IMMUNODEFICIENCY, AND HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUSES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-08-10 | — | — | US | disclosed |
| US-6673830-B2 | COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | disclosed |
| US-6514995-B1 | Metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020086898-A1 | Calanolide and related antiviral compounds, compositions, and uses thereof | BOYD MICHAEL R (US) | 2002-07-04 | — | — | US | disclosed |
| EP-0699202-B1 | CALANOLIDE AND RELATED ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | US HEALTH (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5859049-A | ANTIHEPATITIS B COMPRISING CALANOLIDE A AND B, DIHYDROCALANOLIDE A AND B, COSTATOLIDE, DIHYDROCOSTATOLIDE, SOULATTROLIDE, AND DIHYDROSOULATTROLIDE. | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-01-12 | — | — | US | disclosed |
| US-5591770-A | TREATING HUMAN T-CELL LYMPHOMA/LEUKEMIA INFECTIONS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086898-A1 | Calanolide and related antiviral compounds, compositions, and uses thereof | ZC3HAV1, RPL35, ZC3HAV1L | MAPT 2373/4885LMNA 4249/4885POLB 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.